CN112826889A - Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease - Google Patents
Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease Download PDFInfo
- Publication number
- CN112826889A CN112826889A CN202110242233.2A CN202110242233A CN112826889A CN 112826889 A CN112826889 A CN 112826889A CN 202110242233 A CN202110242233 A CN 202110242233A CN 112826889 A CN112826889 A CN 112826889A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- fatty liver
- alcoholic fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Abstract
The invention discloses a traditional Chinese medicine composition for treating non-alcoholic fatty liver disease, which is prepared from the following raw material medicines in parts by mass: 1-30 parts of sun-dried ginseng, 1-50 parts of thunberg fritillary bulb, 1-20 parts of almond, 1-60 parts of salvia miltiorrhiza, 1-30 parts of lotus leaf, 1-20 parts of rhizoma alismatis, 1-80 parts of hawthorn and 1-60 parts of gynostemma pentaphylla, and the compatibility can effectively reduce the increase of ALT (serum alanine aminotransferase) and AST (aspartate aminotransferase) caused by non-alcoholic fatty liver, reduce the levels of cholesterol (TC), Triglyceride (TG) and low-density lipoprotein (LDL-C) of non-alcoholic fatty liver rats, reduce the pathological change of the liver of non-alcoholic fatty liver model animals and obtain better curative effect in clinical observation.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition, which is composed of 8 traditional Chinese medicines such as sun-dried ginseng, thunberg fritillary bulb, bitter apricot seed, salvia miltiorrhiza, lotus leaf, rhizoma alismatis, hawthorn, gynostemma pentaphylla and the like, and the compatibility of the traditional Chinese medicines can effectively reduce the elevation of ALT (serum alanine aminotransferase) and AST (aspartate aminotransferase) caused by non-alcoholic fatty liver, reduce the levels of cholesterol (TC), Triglyceride (TG) and low-density lipoprotein (LDL-C) of a rat with the non-alcoholic fatty liver, lighten the liver pathological change of a model animal with the non-alcoholic fatty liver, and obtain better curative effect in clinical observation, and belongs to the technical field of medicines.
Background
NAFLD (non alcoholic fatty liver disease) refers to a pathological syndrome caused by liver damage factors excluding alcoholic factors and other causes such as viral hepatitis and hepatolenticular degeneration, and is mainly characterized by the occurrence of steatosis and excessive deposition of fat in liver parenchymal cells. Clinically, the main pathological changes include simple non-alcoholic fatty liver disease, non-alcoholic fatty hepatitis, liver fibrosis and cirrhosis. With the change of dietary habits, NAFLD has a tendency of being younger in recent years, and according to the results of epidemiological investigation, the change range of the prevalence rate of fatty liver in China is 10.2% -22.3%, which is the most main reason for abnormal liver function performance in physical examination of healthy people, and the nafLD can also accelerate the progress of other types of liver diseases, and is an important prophase lesion of cryptogenic liver cirrhosis, so that the NAFLD has great importance for the prevention and treatment of fatty liver at home and abroad.
Although the traditional Chinese medicine has no disease name of fatty liver, the clinical manifestations of the traditional Chinese medicine are similar to the categories of 'accumulation', 'hypochondriac pain', 'fullness and fullness', 'turbid phlegm', 'cellulitis', and the like. At present, the dialectical evidence of the traditional Chinese medicine for treating NAFLD generally considers that the pathogenesis of NAFLD is related to phlegm, turbidity, stasis and heat, but the inventor finds that qi deficiency is one of the pathogenesis of the traditional Chinese medicine in long-term clinical diagnosis and treatment. Therefore, based on the discovery of the pathogenesis of NAFLD by the inventor in clinic, the treatment principle of tonifying qi and activating blood, purging turbid pathogen and removing blood stasis is creatively provided, and the formula of' sun-dried ginseng, thunberg fritillary bulb, almond, salvia miltiorrhiza, lotus leaf, rhizoma alismatis, hawthorn, gynostemma pentaphylla and the like is used for forming an agreement formula, so that good curative effect is obtained clinically.
Disclosure of Invention
The invention aims to provide a new treatment method and prescription for treating NAFLD (NAFLD) by using traditional Chinese medicine, and is characterized by combining qi tonifying and turbidity discharging. In the formula, the sun-dried ginseng is used as a monarch drug to greatly supplement primordial qi, promote the production of body fluid, tonify the lung and strengthen the spleen, ensure the blood to follow qi, and remove blood stasis and remove stagnation; bitter apricot seeds are compatible with the sun-dried ginseng, walk through lung qi to regulate qi movement, and the lung and the large intestine are exterior and interior to lower turbid qi, so that the bitter apricot seeds are beneficial to being discharged out of the body; the two herbs are used together as monarch drug. The salvia miltiorrhiza and the hawthorn are used as ministerial drugs which help the monarch drugs to promote blood circulation, remove blood stasis and remove fat; lotus leaf and alisma orientale are adjuvant drugs for purging turbid pathogen and reducing blood fat; zhe Bei mu is a guiding drug.
The technical scheme adopted by the invention is as follows:
a traditional Chinese medicine composition for treating non-alcoholic fatty liver disease is prepared from the following raw medicines in parts by mass: 1-60 parts of sun-dried ginseng, 1-50 parts of thunberg fritillary bulb, 1-20 parts of bitter almond, 1-60 parts of salvia miltiorrhiza, 1-30 parts of lotus leaf, 1-20 parts of rhizoma alismatis, 1-80 parts of hawthorn and 1-60 parts of gynostemma pentaphylla.
The traditional Chinese medicine composition for treating the non-alcoholic fatty liver disease, disclosed by the invention, preferably comprises the following raw material medicines in parts by mass: 1-20 parts of sun-dried ginseng, 10-50 parts of thunberg fritillary bulb, 5-15 parts of bitter almond, 10-50 parts of salvia miltiorrhiza, 1-20 parts of lotus leaf, 1-10 parts of rhizoma alismatis, 1-30 parts of hawthorn and 1-30 parts of gynostemma pentaphylla.
The traditional Chinese medicine composition for the non-alcoholic fatty liver disease, disclosed by the invention, particularly preferably comprises the following raw material medicines in parts by mass: 6 parts of sun-dried ginseng, 10 parts of thunberg fritillary bulb, 9 parts of bitter almond, 15 parts of salvia miltiorrhiza, 15 parts of lotus leaves, 10 parts of rhizoma alismatis, 12 parts of hawthorn and 30 parts of gynostemma pentaphylla.
Further, the traditional Chinese medicine composition for treating the non-alcoholic fatty liver disease is a water extract of astragalus membranaceus, thunberg fritillary bulb, bitter apricot seeds, salvia miltiorrhiza, lotus leaves, rhizoma alismatis, hawthorn and gynostemma pentaphylla; the water extract is prepared by the following method: taking the optimized prescription amount, adding 10 times of water (W/V), soaking for 30 minutes, decocting twice, each time for 1 hour, filtering, combining the filtrates, and concentrating to obtain the water extract of the composition.
The relative density of the water extract is 500 mg-1000 mg/mL.
The invention has the following beneficial effects: the treatment principle and the drug compatibility of the invention come from clinical practice, the compatibility is reasonable, and the compatibility of astragalus and almond has very good curative effect through pharmacodynamic verification.
Drawings
FIG. 1 is a pathological section of liver of rats in a blank group (x 200 times) according to example 3;
FIG. 2 is a pathological section (200 times) of liver of rat in the model group of example 3;
FIG. 3 is a pathological section of liver of rats of prescription 1 group of example 3 (. times.200 times);
FIG. 4 is a liver pathological section (200 times) of rats of prescription 2 group of example 3;
Detailed Description
The invention will be further described with reference to specific examples, but the scope of the invention is not limited thereto:
example 1: influence of different traditional Chinese medicine compatible water extracts on weight of fatty liver model rat
(1) Materials: one or more Chinese medicinal materials selected from radix Ginseng, Bulbus Fritillariae Thunbergii, semen Armeniacae amarum, Saviae Miltiorrhizae radix, folium Nelumbinis, Alismatis rhizoma, fructus crataegi, and herba Gynostemmatis.
Preparation of formula 1 aqueous extract: weighing 6g of sun-dried ginseng, 10g of thunberg fritillary bulb, 9g of bitter almond, 15g of salvia miltiorrhiza, 15g of lotus leaf, 10g of rhizoma alismatis, 12g of hawthorn and 30g of gynostemma pentaphylla, adding 10 times of water (W/V), soaking for 30 minutes, decocting twice, each time for 1 hour, filtering, combining the filtrates of the two times, and concentrating to obtain a water extract with the concentration of 3 g/ml.
Preparation of formula 2 aqueous extract: weighing 6g of sun-dried ginseng, 15g of salvia miltiorrhiza, 15g of lotus leaf, 10g of rhizoma alismatis, 12g of hawthorn and 30g of gynostemma pentaphylla, adding 10 times of water (W/V), soaking for 30 minutes, decocting twice for 1 hour each time, filtering, combining the filtrates, and concentrating to obtain a water extract with the concentration of 3 g/ml.
Experimental animals: clean SD mouse, male, 180-220 g.
(2) The experimental method comprises the following steps: after 40 healthy male SD rats were adaptively fed for one week, the rats were randomly divided into a blank group, a model group, a formula 1 group and a formula 2 group, 10 rats in each group, the blank group was fed with a basal diet, and the other three groups were fed with a high-fat diet (the formula of the high-fat diet was 20% sucrose, 15% lard, 1.2% cholesterol, 0.2% sodium cholate, 10% casein, 0.6% calcium hydrogen phosphate, 0.4% mountain flour, 0.4% premix, 52.2% basal diet), and freely drunk and eaten. After high fat feeding for 5 weeks, the administration is started, and the blank group and the model group are subjected to intragastric administration by purified water; prescription 1 group was administered prescription 1 aqueous extract for intragastric administration (13.1g/kg rat body weight); prescription 2 group was administered with prescription 2 water extract (13.1g/kg rat body weight) once daily for 12 weeks.
(3) The experimental results are as follows: the rats in each group were close in weight when grouped, and the difference was not statistically significant (n ═ 10, p > 0.05); after the high-fat breeding for 5 weeks, the body weights of the model group, the prescription 1 group and the prescription 2 group are obviously higher than those of the blank group, and the difference has statistical significance (n is 10, p is less than 0.05); after the administration of the drug, the body weight of rats in the model group is obviously higher than that of the blank group, the prescription 1 group and the prescription 2 group, the difference is statistically significant, (n is 10, p is less than 0.05), the difference between the prescription 1 group and the blank group is not statistically significant (n is 10, p is more than 0.05), and the difference between the prescription 2 group and the blank group is statistically significant (n is 10, p is less than 0.05). Therefore, the formula 1 can effectively control the body weight of the fatty liver model rat, and the curative effect is better than that of the formula 2 group. See table 1 for experimental data.
Table 1: weight change data (SI value, n ═ 10) for rats in each group
Indicates that the difference is statistically significant compared to the normal group (p <0.05, n ═ 10);
# denotes that the difference was statistically significant compared to the model group (p <0.05, n ═ 10)
Example 2: influence of different Chinese medicinal compositions on serum liver enzyme and blood fat of fatty liver model rat
(1) Experimental materials were the same as in example 1
(2) Experimental method the same as in example 1
(3) Detection indexes are as follows: on the last day of the fifth week and the last day of the 17 th week, fasting was performed for 12 hours without water deprivation, blood was collected from the retro-orbital venous plexus of rats, serum was fractionated, and the serum contents of alanine Aminotransferase (ALT), aspartate Aminotransferase (AST), cholesterol (TC), Triglyceride (TG) and low-density lipoprotein (LDL-C) in each group of rats were measured using a fully automatic biochemical analyzer.
(4) Serum liver enzyme test results: after the model building is completed, compared with a blank group, the serum ALT and AST of rats in the model group, the prescription 1 group and the prescription 2 group are obviously increased, and the difference has statistical significance (p is less than 0.05, and n is 10). After the administration at the end of 17 weeks, the serum ALT and AST of the rats in the prescription 1 group are close to the normal group, the difference is not statistically significant (p is 0.05, and n is 10), the serum ALT and AST of the rats in the model group and the prescription 2 group are higher than the normal group, and the difference is statistically significant (p is 0.05, and n is 10); the ALT and AST of the serum of the rats in the prescription 1 group and the prescription 2 group are lower than those in the model group, and the difference is statistically significant (p is less than 0.05, and n is 10); the serum ALT and AST of the prescription 1 group rats are lower than those of the prescription 2 group, and the difference is not statistically significant (p >0.05, n ═ 10). The curative effect of the prescription on the ALT and AST of the model rat with the non-alcoholic fatty liver disease is obviously better than that of the prescription 2, and the experimental data are shown in a table 3.
Table 3: rat serum liver enzyme data (n ═ 10)
Indicates that the difference is statistically significant compared to the normal group (p <0.05, n ═ 10);
# denotes that the difference was statistically significant compared to the model group (p <0.05, n ═ 10)
(5) The experimental result of the blood fat content is as follows: after the model is made, compared with the blank group, the serum TC, TG and LDL-C of the rats in the model group, the prescription 1 group and the prescription 2 group are obviously increased, and the difference has statistical significance (p is less than 0.05, and n is 10). After 17 weeks of last administration, the serum TC and LDL-C of the rats in the prescription 1 group were close to normal, the difference was not statistically significant (p >0.05, n ═ 10), TG was higher than that in the normal group, the difference was statistically significant (p <0.05, n ═ 10), and the serum TC, TG and LDL-C of the rats in the prescription 1 group was lower than that in the model group, and the difference was statistically significant (p <0.05, n ═ 10). The serum TC, TG and LDL-C of the rats in the model group and the prescription 2 group are higher than those in the normal group, and the difference is statistically significant (p <0.05, n is 10). Formula 2 groups had lower serum TG, LDL-C than the model group, with statistical differences (p <0.05, n ═ 10). Formula 1 rat sera TG, LDL-C were both lower than formula 2, with statistical differences (p <0.05, n ═ 10). The prescription 1 is obviously better than the prescription 2 in the curative effect of reducing TG and LDL-C of nonalcoholic fatty liver model rats, and the experimental data are shown in a table 4.
Table 4: blood lipid concentration data of rat (n ═ 10)
Indicates that the difference is statistically significant compared to the normal group (p <0.05, n ═ 10);
# denotes that the difference was statistically significant compared to the model group (p <0.05, n ═ 10)
The term "the difference" means that the difference is statistically significant compared with the prescription 1 (p <0.05, n ═ 10)
Example 3: influence of different traditional Chinese medicine compositions on liver pathology of fatty liver model rat
(1) Experimental materials were the same as in example 1
(2) Experimental method the same as in example 1
(3) The experimental method comprises the following steps: the rats after blood collection are sacrificed, the livers of the rats are rapidly separated, HE staining is carried out after neutral formaldehyde fixation, and pathological changes are observed under a microscope.
(3) The experimental results are as follows: the blank group of rats has normal liver tissue structure, clear liver sinuses, orderly liver cable arrangement, cytoplasmic red staining and normal cell morphology; the liver cells of the model group are slightly turbid and swollen, severe steatosis of stem cells can be seen, mainly diffuse artillery fat deformation can be seen, punctate or focal necrotic cells with different degrees can be seen, and lymphocyte infiltration can be seen; formula 1 group of rats have mild nepheloid cells of liver tissues, clear cell structures, uniform cytoplasm and sporadic fatty degeneration cells; the liver tissue structure of the prescription 2 group is slightly disordered, and the steatosis cells are increased, occasionally inflammation and lymphocyte infiltration are caused. See fig. 1-4 for details.
It can be seen that formula 1 has significantly better effect on the change of liver of rat in fatty liver model than that of the model group and formula 2, and can effectively reduce the number of fat-induced degeneration cells in liver tissue and reduce the inflammatory reaction of liver tissue.
Claims (6)
1. The traditional Chinese medicine composition for treating the non-alcoholic fatty liver disease is characterized by being prepared from the following raw material medicines in parts by mass: 1-60 parts of sun-dried ginseng, 1-50 parts of thunberg fritillary bulb, 1-20 parts of almond, 1-60 parts of salvia miltiorrhiza, 1-30 parts of lotus leaf, 1-20 parts of rhizoma alismatis, 1-80 parts of hawthorn and 1-60 parts of gynostemma pentaphylla.
2. The traditional Chinese medicine composition for treating non-alcoholic fatty liver disease of claim 1, wherein the traditional Chinese medicine composition comprises the following raw material medicines in parts by mass: 1-20 parts of sun-dried ginseng, 10-50 parts of thunberg fritillary bulb, 5-15 parts of almond, 10-50 parts of salvia miltiorrhiza, 1-20 parts of lotus leaf, 1-10 parts of rhizoma alismatis, 1-30 parts of hawthorn and 1-30 parts of gynostemma pentaphylla.
3. The traditional Chinese medicine composition for treating non-alcoholic fatty liver disease of claim 1, wherein the traditional Chinese medicine composition comprises the following raw material medicines in parts by mass: 6 parts of sun-dried ginseng, 10 parts of thunberg fritillary bulb, 9 parts of almond, 15 parts of salvia miltiorrhiza, 15 parts of lotus leaf, 10 parts of rhizoma alismatis, 12 parts of hawthorn and 30 parts of gynostemma pentaphylla.
4. The traditional Chinese medicine composition for treating non-alcoholic fatty liver disease of claim 1, wherein the traditional Chinese medicine composition is an aqueous extract of sun-dried ginseng, thunberg fritillary bulb, almond, red sage root, lotus leaf, rhizoma alismatis, hawthorn fruit and gynostemma pentaphylla.
5. The traditional Chinese medicine composition for treating non-alcoholic fatty liver disease of claim 1, wherein the composition is prepared by the following method: taking sun-dried ginseng, thunberg fritillary bulb, almond, salvia miltiorrhiza, lotus leaves, rhizoma alismatis, hawthorn and gynostemma pentaphylla according to the formula amount, and preparing water extracts according to the following steps: soaking in 10 times of water for 30 min, decocting twice, each for 1 hr, filtering, mixing filtrates, and concentrating to obtain water extract.
6. The traditional Chinese medicine composition for treating non-alcoholic fatty liver disease according to claim 1, which is characterized by comprising the following therapeutic principles: replenishing qi and activating blood circulation, purging turbid pathogen and removing blood stasis, taking sun-dried ginseng, thunberg fritillary bulb, almond, salvia miltiorrhiza, lotus leaf, rhizoma alismatis, hawthorn and gynostemma pentaphylla to form a prescription according to a certain proportion under the guidance of treatment rules, and preparing the oral medicine for treating the non-alcoholic fat through water decoction and concentration processes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110242233.2A CN112826889A (en) | 2021-03-04 | 2021-03-04 | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110242233.2A CN112826889A (en) | 2021-03-04 | 2021-03-04 | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112826889A true CN112826889A (en) | 2021-05-25 |
Family
ID=75934616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110242233.2A Pending CN112826889A (en) | 2021-03-04 | 2021-03-04 | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112826889A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114796366A (en) * | 2022-03-30 | 2022-07-29 | 广州中医药大学第一附属医院 | Traditional Chinese medicine composition and application thereof |
| CN115475193A (en) * | 2022-11-08 | 2022-12-16 | 上海中医药大学附属曙光医院 | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1943762A (en) * | 2006-09-09 | 2007-04-11 | 刘志勇 | A Medicine for treatment of fatty liver and its preparation method |
| CN1985978A (en) * | 2006-12-13 | 2007-06-27 | 上海莱博生物科技有限公司 | Compound preparation for reducing fat deposit in liver and alleviating fatty degeneration of liver cell |
| CN103919878A (en) * | 2014-05-04 | 2014-07-16 | 白求恩医科大学制药厂 | Medicine for treating fatty liver and hyperlipidaemia and preparation process thereof |
-
2021
- 2021-03-04 CN CN202110242233.2A patent/CN112826889A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1943762A (en) * | 2006-09-09 | 2007-04-11 | 刘志勇 | A Medicine for treatment of fatty liver and its preparation method |
| CN1985978A (en) * | 2006-12-13 | 2007-06-27 | 上海莱博生物科技有限公司 | Compound preparation for reducing fat deposit in liver and alleviating fatty degeneration of liver cell |
| CN103919878A (en) * | 2014-05-04 | 2014-07-16 | 白求恩医科大学制药厂 | Medicine for treating fatty liver and hyperlipidaemia and preparation process thereof |
Non-Patent Citations (4)
| Title |
|---|
| 余论文主编: "《中和医案》", 30 November 2013, 中原农民出版社 * |
| 朱丹等: "姚乃礼辨治脂肪肝经验", 《中医杂志》 * |
| 祝佳等: "骆传佳教授分型论治非酒精性脂肪性肝病的经验", 《中西医结合肝病杂志》 * |
| 陈高峰等: "丹泽降脂方防治大鼠非酒精性脂肪肝的实验研究", 《中西医结合肝病杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114796366A (en) * | 2022-03-30 | 2022-07-29 | 广州中医药大学第一附属医院 | Traditional Chinese medicine composition and application thereof |
| CN114796366B (en) * | 2022-03-30 | 2023-08-01 | 广州中医药大学第一附属医院 | Traditional Chinese medicine composition and application thereof |
| CN115475193A (en) * | 2022-11-08 | 2022-12-16 | 上海中医药大学附属曙光医院 | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and application thereof |
| CN115475193B (en) * | 2022-11-08 | 2023-06-20 | 上海中医药大学附属曙光医院 | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03003446A (en) | Novel medicinal herbal composition for treating liver diseases and hiv. | |
| JP2004161732A (en) | Natural medicine preparation for treatment of hiv/aids patient | |
| CN108524814A (en) | A kind of Chinese medicine composition and preparation method thereof for reducing blood glucose | |
| CN112826889A (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease | |
| CN113713039A (en) | Traditional Chinese medicine composition for treating membranous nephropathy and application thereof | |
| CN110604773B (en) | Composition for regulating lipid metabolism disorder and preparation method and application thereof | |
| CN106177477A (en) | A kind of health composition for blood sugar lowering, blood fat reducing and blood pressure lowering | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN104173585A (en) | Adaptogen preparation containing rhodiola rosea and preparation method thereof | |
| CN104225472B (en) | A kind of Chinese medicine preparation and preparation method and purposes for treating Oral mucosal lesion | |
| CN110898182A (en) | Traditional Chinese medicine for treating liver-yang-hyperactivity and spleen-deficiency type ulcerative colitis and preparation system thereof | |
| CN114748603B (en) | Pharmaceutical composition for preventing and treating new coronavirus pneumonia from changing or restoring yang and application thereof | |
| CN106110072A (en) | A kind of Herba Lophatheri compositions with effect of weight reducing and preparation method thereof | |
| CN102526672B (en) | Traditional Chinese medicine composition, applications and preparation method | |
| CN104056242A (en) | Traditional Chinese medicine composition for treating acute cholecystitis and preparation method thereof | |
| CN105327115B (en) | A kind of prevention and treatment type II diabetes Phellinus is logical to rush down formula and preparation process | |
| CN107029074A (en) | A kind of pharmaceutical composition and preparation method and purposes for treating fatty liver | |
| CN101011436A (en) | Medical usage of total phytosterone from achyranthes | |
| CN109999076A (en) | It is a kind of adjust reverse cholesterol transport Chinese medicine composition and its application | |
| CN113425788B (en) | Traditional Chinese medicine composition for treating liver diseases and preparation method and application thereof | |
| CN104225471B (en) | A kind of compound preparation and preparation method for the treatment of oral lichen planus | |
| CN114246337B (en) | Composition for strengthening spleen, eliminating dampness and losing weight as well as preparation method and application thereof | |
| CN114796417B (en) | Blood sugar reducing traditional Chinese medicine formula and preparation method thereof | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
| TWI749286B (en) | Composition for regulating intestinal flora balance, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210525 |